Literature DB >> 14695663

Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease.

Takeshi Tanaka1, Kazuaki Inoue, Yukiko Hayashi, Aki Abe, Kyoko Tsukiyama-Kohara, Hideko Nuriya, Yoshikazu Aoki, Ryuji Kawaguchi, Kiichi Kubota, Makoto Yoshiba, Morio Koike, Satoshi Tanaka, Michinori Kohara.   

Abstract

The clinical and virological significance of low-level viremia by hepatitis B virus (HBV) in hepatitis C virus (HCV)-infected patients remains unclear. HBV-DNA and HCV-RNA were, therefore, quantitatively analyzed in livers and sera from co-infected patients. HBV-DNA and HCV-RNA were quantitated using real-time detection of polymerase chain reaction (RTD-PCR), based on Taq-Man chemistry, in 220 non-HCV-infected healthy volunteers and 93 HCV-infected patients without detectable HBsAg. Serum HBV-DNA was detected in 4 (1.8%) of 220 non-HCV-infected healthy volunteers and 32 (34.4%) of 93 HCV-infected patients without detectable HBsAg. HCV-infected patients displayed higher frequency of HBV infection than healthy volunteers (P < 0.0001). Hepatocellular carcinoma (HCC) was more frequent among co-infected patients than among HCV mono-infected patients (P < 0.001). However, quantities of HBV-DNA in sera from co-infected patients were very low (8-19,000 copies/ml). HBV-DNA was detected in liver tissue from co-infected patients at 2-20 copies per 100 hepatocytes, accounting for 1/1,000 to 1/10,000 of HBsAg positive patients. In livers of patients with HCC and HCV or HBV mono-infection, the viruses existed predominantly in non-cancerous tissue, with levels 10- to 1,000-fold and 1- to 100-fold higher than in cancerous tissue, respectively. In contrast, patients co-infected with HCV and HBV displayed decreased HBV levels in non-cancerous tissue, but no change in cancerous tissue. These results indicate that low-level HBV infection exists in HCV-infected patients. HCC was more common among HCV/HBV co-infected patients than among HCV mono-infected patients. HCV might initiate hepatocarcinogenesis, but does not necessarily determine progression to HCC. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695663     DOI: 10.1002/jmv.10566

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

Review 1.  MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

Authors:  Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu
Journal:  World J Hepatol       Date:  2015-03-27

2.  Detection of hepatitis B and C viruses in almost all hepatocytes by modified PCR-based in situ hybridization.

Authors:  Hideko Nuriya; Kazuaki Inoue; Takeshi Tanaka; Yukiko Hayashi; Tsunekazu Hishima; Nobuaki Funata; Kyosuke Kaji; Seishu Hayashi; Shuichi Kaneko; Michinori Kohara
Journal:  J Clin Microbiol       Date:  2010-08-25       Impact factor: 5.948

3.  The identification of highly efficacious functionalised tetrahydrocyclopenta[c]pyrroles as inhibitors of HBV viral replication through modulation of HBV capsid assembly.

Authors:  Andrew G Cole; Steven G Kultgen; Nagraj Mani; Andrzej Ardzinski; Kristi Yi Fan; Emily P Thi; Bruce D Dorsey; Kim Stever; Tim Chiu; Sunny Tang; Owen Daly; Janet R Phelps; Troy Harasym; Andrea Olland; Robert K Suto; Michael J Sofia
Journal:  RSC Med Chem       Date:  2022-01-19

4.  Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Authors:  Nagraj Mani; Andrew G Cole; Janet R Phelps; Andrzej Ardzinski; Kyle D Cobarrubias; Andrea Cuconati; Bruce D Dorsey; Ellen Evangelista; Kristi Fan; Fang Guo; Haitao Guo; Ju-Tao Guo; Troy O Harasym; Salam Kadhim; Steven G Kultgen; Amy C H Lee; Alice H L Li; Quanxin Long; Sara A Majeski; Richeng Mao; Kevin D McClintock; Stephen P Reid; Rene Rijnbrand; Nicholas M Snead; Holly M Micolochick Steuer; Kim Stever; Sunny Tang; Xiaohe Wang; Qiong Zhao; Michael J Sofia
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 5.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

6.  Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase.

Authors:  Tomohiro Nishimura; Michinori Kohara; Kosuke Izumi; Yuri Kasama; Yuichi Hirata; Ying Huang; Masahiro Shuda; Chise Mukaidani; Takashi Takano; Yuko Tokunaga; Hideko Nuriya; Masaaki Satoh; Makoto Saito; Chieko Kai; Kyoko Tsukiyama-Kohara
Journal:  J Biol Chem       Date:  2009-10-27       Impact factor: 5.157

7.  Demonstration of hepatitis C virus RNA with in situ hybridization employing a locked nucleic Acid probe in humanized liver of infected chimeric mice and in needle-biopsied human liver.

Authors:  Kazuya Shiogama; Ken-Ichi Inada; Michinori Kohara; Hidemi Teramoto; Yasuyoshi Mizutani; Takanori Onouchi; Yutaka Tsutsumi
Journal:  Int J Hepatol       Date:  2013-06-18

8.  Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection.

Authors:  Shin-ichiro Nakagawa; Yuichi Hirata; Takeshi Kameyama; Yuko Tokunaga; Yasumasa Nishito; Kazuko Hirabayashi; Junichi Yano; Takahiro Ochiya; Chise Tateno; Yasuhito Tanaka; Masashi Mizokami; Kyoko Tsukiyama-Kohara; Kazuaki Inoue; Makoto Yoshiba; Akinori Takaoka; Michinori Kohara
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

9.  Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C.

Authors:  Sayeh Ezzikouri; Kiminori Kimura; Hajime Sunagozaka; Shuichi Kaneko; Kazuaki Inoue; Tomohiro Nishimura; Tsunekazu Hishima; Michinori Kohara; Kyoko Tsukiyama-Kohara
Journal:  EBioMedicine       Date:  2015-04-13       Impact factor: 8.143

10.  Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice.

Authors:  Chise Tateno; Yosuke Kawase; Yoshimi Tobita; Satoko Hamamura; Hiroki Ohshita; Hiroshi Yokomichi; Harumi Sanada; Masakazu Kakuni; Akira Shiota; Yuha Kojima; Yuji Ishida; Hiroshi Shitara; Naoko A Wada; Hiromi Tateishi; Masayuki Sudoh; Shin-Ichiro Nagatsuka; Kou-Ichi Jishage; Michinori Kohara
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.